Prognostic significance of receptor conversion following neoadjuvant therapy in breast cancer: a systematic review & meta-analysis

Prognostic significance of receptor conversion following neoadjuvant therapy in breast cancer: a systematic review & meta-analysis

Purpose: Receptor conversion following neoadjuvant therapy in breast cancer may influence prognosis and adjuvant treatment decisions. This systematic review and meta-analysis evaluated the prognostic significance of changes in hormone receptor (HR) and HER2 status after neoadjuvant therapy. Methods:...

Full description

Saved in:

Bibliographic Details
Main Authors:	Gavin P. Dowling, Gordon R. Daly, Cian M. Hehir, Maen M. AlRawasdeh, Gavin G. Calpin, Sami Almasri, Sinead Toomey, Leonie S. Young, Bryan T. Hennessey, Arnold D.K. Hill
Format:	Article
Language:	English
Published:	Elsevier 2025-08-01
Series:	Breast
Subjects:	Breast cancer Receptor conversion HER2 Hormone receptor Neoadjuvant therapy Prognosis
Online Access:	http://www.sciencedirect.com/science/article/pii/S0960977625005338
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

HER2 and hormone receptor conversion after neoadjuvant therapy for breast cancer
by: Jing Wang, et al.
Published: (2025-06-01)

Pathologic Response and Survival Outcomes on HER2-Low vs. HER2-Zero in Breast Cancer Receiving Neoadjuvant Chemotherapy
by: Rumeysa Colak, et al.
Published: (2025-06-01)

Receptor Status Differences in Prognosis for Breast Cancer
by: Yelda Deligöz Bildacı, et al.
Published: (2024-07-01)

Neoadjuvant chemotherapy response in androgen receptor-positive triple-negative breast cancer: potential predictive biomarkers and genetic alterations
by: Ming Li, et al.
Published: (2025-03-01)

Assessment of ESR1, PGR, ERBB2, and MKI67 mRNA in Hormone Receptor‐Positive Early Breast Cancer: A Cross‐Sectional Study
by: Hamid Rezvani, et al.
Published: (2025-07-01)

De-escalated neoadjuvant nab-paclitaxel combined with pyrotinib and trastuzumab in intrinsic HER2-enriched breast cancer (NJMU-BC01): a multicenter, single-arm, phase 2 trialResearch in context
by: Hong Pan, et al.
Published: (2025-08-01)

Camrelizumab in combination with doxorubicin, cisplatin, ifosfamide, and methotrexate in neoadjuvant treatment of resectable osteosarcoma: A prospective, single‐arm, exploratory phase II trial
by: Qinglian Tang, et al.
Published: (2024-09-01)

Revealing the role of RAB27 in HER receptor family expression and signaling in melanoma cells
by: Katarzyna Horodecka, et al.
Published: (2025-03-01)

Pathologic response rates in HER2-low versus HER2-zero early breast cancer patients receiving neoadjuvant therapy: a systematic review and meta-analysis
by: Francisco Cezar Aquino de Moraes, et al.
Published: (2025-03-01)

Immunohistochemical Expression of ROS1 in invasive ductal carcinoma of breast in association with hormonal receptor status and Her2Neu expression
by: Muhammad Umair, et al.
Published: (2024-10-01)

Switching to T-DM1 remains justified in patients with HER2-negative residual invasive breast cancer after neoadjuvant therapy
by: Charles E. Geyer, Jr., et al.
Published: (2025-06-01)

Neoadjuvant compared to adjuvant chemotherapy combined with trastuzumab in patients with HER2-positive breast cancer: a register-based cohort study
by: S. Hosseini-Mellner, et al.
Published: (2024-12-01)

Pilot clinical trial of neoadjuvant toll-like receptor 7 agonist (Imiquimod) immunotherapy in early-stage oral squamous cell carcinoma
by: Angela J. Yoon, et al.
Published: (2025-01-01)

Assessment of the receptor status in primary breast cancer with synchronous loco regional metastases: prognostic and clinical role?
by: O. O. Gordeeva, et al.
Published: (2019-04-01)

Liposomal oncolytic adenovirus as a neoadjuvant therapy for triple-negative breast cancer
by: Jaimin R. Shah, et al.
Published: (2025-05-01)

Improving treatment outcomes for patients with HER2‑positive breast cancer using neoadjuvant double HER2 blockade
by: V. F. Semiglazov, et al.
Published: (2024-11-01)

Analysis of the Clinical Molecular Characteristics and Neoadjuvant Chemotherapy Response in Patients with Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer and Axillary Lymph Node Metastasis
by: Jin-Ping Ma, et al.
Published: (2022-06-01)

Efficacy of adjuvant capecitabine in triple-negative breast cancer with residual disease after neoadjuvant therapy: a real-world study
by: Youzhao Ma, et al.
Published: (2025-06-01)

A prospective, phase II, neoadjuvant study based on chemotherapy sensitivity in HR+/HER2‐ breast cancer‐FINEST study
by: Li Chen, et al.
Published: (2025-04-01)

Predictive factors for outcome in HER2-low breast cancer patients after neoadjuvant chemotherapy
by: Yingbo Shao, et al.
Published: (2025-03-01)

Case report: Patients with positive HER-2 amplification locally advanced gastroesophageal junction cancer achieved pathologic complete response with the addition of pembrolizumab to chemotherapy plus trastuzumab as neoadjuvant therapy
by: Huanhuan Li, et al.
Published: (2025-02-01)

Valency-affinity mapping of multivalent liposomes for tunable target cell discrimination
by: Victor A. Garcia, et al.
Published: (2025-12-01)

CLINICAL CHARACTERISTICS OF BREAST CANCER WITH STEROID RECEPTORS EXPRESSION AND HER2 AMPLIFICATION
by: F. V. Moiseenko, et al.
Published: (2017-02-01)

Lapatinib plus transtuzumab for HER-2 positiva metastatic breast cancer: Experience of use
by: C. García-Muñoz, et al.
Published: (2014-03-01)

Clinical significance of changes in the expression level of markers of surrogate breast cancer subtypes in recurrent and metastatic foci (literature review)
by: Yu. S. Krumin, et al.
Published: (2021-03-01)

Incidence and Prognostic Significance of Hormonal Receptors and HER2 Status Conversion in Recurrent Breast Cancer: A Retrospective Study in a Single Institute
by: Einas M. Yousef, et al.
Published: (2025-03-01)

Androgen receptor expression in triple negative breast cancer: an Algerian population study
by: Amel Hedjem, et al.
Published: (2025-12-01)

The role of epidermal growth factor receptor (EGFR) in the efficacy of neoadjuvant chemotherapy in triple-negative breast cancer patients
by: N. N. Babyshkina, et al.
Published: (2020-04-01)

ASSESSMENT OF RECEPTOR CONVERSION ROLE FOR ADVANCED BREAST CANCER ON THE CHEMORESISTANCE OCCURRENCE
by: Oleksii V. Movchan, et al.
Published: (2025-03-01)

Discussion on the mechanism of HER2 resistance in esophagogastric junction and gastric cancer in the era of immunotherapy
by: Yan Zhang, et al.
Published: (2025-12-01)

HER2-low breast cancer. Diagnostics, treatment and its adverse events
by: Hanna Bartkowiak, et al.
Published: (2024-12-01)

Analysis of methylation features associated with neoadjuvant efficacy in HER2-positive breast cancer
by: Zibai Guo, et al.
Published: (2025-08-01)

Response and prognosis to neoadjuvant chemotherapy in women early breast cancer of HER2-low status
by: Yongtao Li, et al.
Published: (2025-06-01)

Concordance Between ER, PR, HER2 neu Receptors Before and After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer
by: Taha Heba F., et al.
Published: (2021-05-01)

Current aspects of systematics, diagnosis and treatment of breast cancer
by: D. N. Strunkin, et al.
Published: (2022-05-01)

Targeted and cytotoxic inhibitors used in the treatment of breast cancer
by: Robert Roskoski Jr.
Published: (2024-12-01)

A population‑based propensity score matching analysis of neoadjuvant compared to adjuvant chemotherapy in luminal breast cancer
by: Chenhui Zheng, et al.
Published: (2025-03-01)

Comparative evaluation of the prognostic significance of molecular tumor markers (estrogen and progesterone receptors, HER-2/neu) and the Nottingham prognostic index in breast cancer
by: V. Sekhri, et al.
Published: (2024-02-01)

Human Epidermal Growth Factor Receptor 2 [HER‐2/neu] Amplification and Microsatellite Stable Status in Gastric and Gastroesophageal Adenocarcinoma: Assessing Frequency and Prognostic Implications at the Cancer Institute of Iran
by: Samaneh Salarvand, et al.
Published: (2025-08-01)

A composite 18F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026)Key Points:
by: Maeve A. Hennessy, et al.
Published: (2025-06-01)